Women s health study low dose aspirin in primary prevention
This presentation is the property of its rightful owner.
Sponsored Links
1 / 6

Women's Health Study: Low-Dose Aspirin in Primary Prevention PowerPoint PPT Presentation


  • 74 Views
  • Uploaded on
  • Presentation posted in: General

Women's Health Study: Low-Dose Aspirin in Primary Prevention Trial. Women's Health Study: Low-Dose Aspirin in Primary Prevention. Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr. Paul M. Ridker.

Download Presentation

Women's Health Study: Low-Dose Aspirin in Primary Prevention

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Women s health study low dose aspirin in primary prevention

Women's Health Study: Low-Dose Aspirin in Primary Prevention Trial

Women's Health Study: Low-Dose Aspirin in Primary Prevention

Presented at

American College of Cardiology

Scientific Sessions 2005

Presented by Dr. Dr. Paul M. Ridker


Women s health study low dose aspirin in primary prevention trial

Women's Health Study: Low-Dose Aspirin in Primary Prevention Trial

39,876 initially healthy† women age ≥ 45

Randomized, blinded, factorial

Placebo

n=19,942

Low-dose Aspirin

100mg on alternate days

n=19,934

  • Endpoints (mean 10.1 years):

    • Combined endpoint of nonfatal MI, nonfatal stroke, and total cardiovascular death.

    • Incidence of total malignant neoplasms of epithelial cell origin.

†: No history of coronary heart disease, cerebrovascular disease, cancer (except nonmelanoma skin cancer), or other major chronic illness; no history of side effects to any of the study medications; not taking aspirin or nonsteroidal antiinflammatory medications (NSAIDs) more than once a week (or were willing to forego their use during the trial); not taking anticoagulants or corticosteroids; and not taking individual supplements of vitamin A, E, or beta carotene more than once a week.

Presented at ACC Scientific Sessions 2005


Womens health study low dose aspirin in primary prevention

Women's Health Study: Low-Dose Aspirin in Primary Prevention Trial

Composite Components:

Primary Composite Endpoint:

Major Cardiovascular Events

Relative Risk [RR] 0.91

95% CI 0.80-1.03

p=0.13

Death from CV Causes

p=0.68

Stroke

p=0.04

MI

p=0.83

Placebo

Placebo

Aspirin

Aspirin

Placebo

Aspirin

  • Baseline characteristics were well matched between the two treatment groups.

  • Among the individual components of the composite endpoint, there was no difference in MI or death from cardiovascular causes, but total stroke was lower in the aspirin group.

Presented at ACC Scientific Sessions 2005


Womens health study low dose aspirin in primary prevention

Women's Health Study: Low-Dose Aspirin in Primary Prevention Trial

Components of Stroke

Transient Ischemic Attack

p=0.01

Gastrointestinal Bleeding Requiring Transfusion

p=0.02

Hemorrhagic Stroke

p=0.31

Ischemic Stroke

p=0.009

Placebo

Placebo

Placebo

Placebo

Aspirin

Aspirin

Aspirin

Aspirin

  • Total stroke was lower in the aspirin group due to a reduction in ischemic stroke.

  • Transient ischemic attack was lower in the aspirin group, but there was a higher incidence of gastrointestinal bleeding requiring transfusion.

Presented at ACC Scientific Sessions 2005


Womens health study low dose aspirin in primary prevention

Women's Health Study: Low-Dose Aspirin in Primary Prevention Trial

Primary Composite Endpoint

(age ≥ 65)

p=0.008

Gastrointestinal Bleeding

(age ≥ 65)

p=0.05

16

44

  • In the subgroup analysis, the primary endpoint was lower in women age ≥65 years (n=4097) (RR 0.74, p=0.008), but did not differ in women <65 years (p<0.001 for interaction).

  • Additionally, the primary endpoint was lower in women who were former or never smokers (RR 0.80, p=0.003) but was higher in current smokers (RR 1.30, p=0.03; p<0.001 for interaction).

Presented at ACC Scientific Sessions 2005


Womens health study low dose aspirin in primary prevention

Women's Health Study: Low-Dose Aspirin in Primary Prevention Trial

  • Among initially healthy women, treatment with low-dose aspirin was not associated with a significant difference in the primary endpoint of major cardiovascular events compared with placebo at a mean 10 year follow-up.

  • Low-dose aspirin has been shown to be effective for secondary prevention following acute coronary syndromes, but data for primary prevention with aspirin in women were limited. The Physicians' Health Study, a randomized trial of aspirin for primary prevention conducted in male physicians showed a reduction in MI and a trend toward an increase in total stroke, unlike the present trial in women which showed no difference in MI and a reduction in total stroke. It is unclear why gender-related differences in aspirin therapy for primary prevention may exist.

  • Benefit with aspirin therapy was observed in the subgroup of women age ≥65 years and non-smokers.

Presented at ACC Scientific Sessions 2005


  • Login